Cardlytics Inc (NASDAQ:CDLX) Receives $33.67 Average Target Price from Analysts

Cardlytics Inc (NASDAQ:CDLX) has been given an average recommendation of “Buy” by the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $33.67.

A number of equities research analysts have weighed in on CDLX shares. Raymond James lifted their price target on shares of Cardlytics from $24.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. set a $43.00 price target on shares of Cardlytics and gave the company a “buy” rating in a research report on Friday, August 9th. ValuEngine lowered shares of Cardlytics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. SunTrust Banks raised their price objective on shares of Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Zacks Investment Research lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th.

In other news, major shareholder Aimia Inc. sold 1,500,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $29.95, for a total value of $44,925,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bryce Youngren sold 88,030 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $29.12, for a total transaction of $2,563,433.60. The disclosure for this sale can be found here. In the last three months, insiders bought 181,830 shares of company stock valued at $6,625,833 and sold 2,821,546 shares valued at $88,248,903. Company insiders own 21.90% of the company’s stock.

A number of institutional investors have recently modified their holdings of CDLX. Marshall Wace LLP purchased a new position in Cardlytics in the first quarter worth approximately $336,000. FMR LLC lifted its stake in Cardlytics by 2.3% in the first quarter. FMR LLC now owns 3,284,572 shares of the company’s stock worth $54,327,000 after acquiring an additional 72,847 shares during the last quarter. Gamco Investors INC. ET AL lifted its stake in Cardlytics by 2.6% in the second quarter. Gamco Investors INC. ET AL now owns 15,850 shares of the company’s stock worth $412,000 after acquiring an additional 400 shares during the last quarter. Tygh Capital Management Inc. lifted its stake in Cardlytics by 17.1% in the second quarter. Tygh Capital Management Inc. now owns 176,237 shares of the company’s stock worth $4,579,000 after acquiring an additional 25,790 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Cardlytics by 177.9% in the second quarter. JPMorgan Chase & Co. now owns 199,301 shares of the company’s stock worth $4,901,000 after acquiring an additional 127,596 shares during the last quarter. Institutional investors own 84.08% of the company’s stock.

Shares of CDLX traded down $0.17 during trading on Monday, reaching $37.95. 249,200 shares of the company traded hands, compared to its average volume of 312,884. Cardlytics has a twelve month low of $9.80 and a twelve month high of $39.83. The stock has a market cap of $886.86 million, a PE ratio of -17.73 and a beta of 1.49. The stock has a 50-day simple moving average of $35.67 and a 200-day simple moving average of $27.28. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.79.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.23. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. The business had revenue of $48.73 million during the quarter, compared to analysts’ expectations of $43.77 million. During the same period last year, the business earned ($0.21) earnings per share. The business’s revenue for the quarter was up 37.0% on a year-over-year basis. On average, equities research analysts predict that Cardlytics will post -1.08 EPS for the current year.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Read More: What are benefits of a growth and income fund?

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.